Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 72

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 72
---

			Total unallocated internal costs

			275,586

			234,409

			41,177

			Total research and development costs

			939,067

			897,305

			41,762

			●

			Research and development (R&D) expenses were $0.9 million for each of the three months ended June 30, 2025 and June 30, 2024, as an increase in EB06-related expenses associated with preparations for the Phase 2 clinical study was offset by a decrease in external research expenses related to EB05. Our R&D expenses consist primarily of employee-related expenses, including salaries, benefits, taxes, travel, and share-based compensation expense for personnel in R&D functions; expenses related to process development and production of product candidates paid to contract manufacturing organizations, including the cost of acquiring, developing, and manufacturing research material; costs associated with clinical activities, including expenses for contract research organizations; and clinical trials and activities related to regulatory filings for our product candidates, including regulatory consultants.

			●

			General and administrative (G&A) expenses were $1.0 million for each of the three months ended June 30, 2025 and June 30, 2024, as a decrease in salaries and related costs was offset by an increase in noncash share-based compensation and professional service fees. Our G&A expenses consist primarily of salaries and related costs for our employees in administrative, executive and finance functions. G&A expenses also include professional fees for legal, accounting, audit, tax and consulting services, insurance, office, and travel expenses.

Total other income decreased by $110,000 to $154,000 for the three months ended June 30, 2025 compared to $264,000 for the same period last year and was composed of the following:

			●

			Grant income decreased by $53,000 to $183,000 for the three months ended June 30, 2025 compared to $236,000 for the three months ended June 30, 2024. The decrease is related to the grant income associated with the activities under the 2023 SIF Agreement.

			●

			Interest income decreased to $600 for the three months ended June 30, 2025 compared to $33,000 for the same period last year primarily due to lower cash balances.

			●

			Foreign exchange loss